Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 14/20 | 0.54 |
| ▸ | MTR | Q99707 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699847 | 0.93 | DHFR (0.52) | DHFRMTRKDM4EALDH1A1HPGD | |
| SCHEMBL6705312 | 0.92 | DHFR (0.49) | DHFRMTRKDM4EALDH1A1HPGD | |
| SCHEMBL6699116 | 0.85 | DHFR (0.61) | DHFRMTR | |
| SCHEMBL10651972 | 0.84 | DHFR (0.54) | DHFRMTR | |
| SCHEMBL6074471 | 0.79 | L3MBTL1 (0.50) | DHFRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6701864 | 0.78 | DHFR (0.59) | DHFRMTR | |
| SCHEMBL10647855 | 0.78 | DHFR (0.56) | DHFRMTR | |
| SCHEMBL6704122 | 0.77 | DHFR (0.66) | DHFRMTR | |
| SCHEMBL10828840 | 0.76 | L3MBTL1 (0.52) | DHFRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6701226 | 0.76 | DHFR (0.73) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | BERRY DAVID ALLEN (US) | 2004-01-08 | — | — | US | claimed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | claimed |
| EP-0103464-B1 | DIAMINOPYRIMIDINES AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-11-17 | — | — | EP | claimed |
| US-4532240-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1985-07-30 | — | — | US | claimed |
| EP-0103464-A2 | Diaminopyrimidines and their production | WARNER-LAMBERT COMPANY (US) | 1984-03-21 | — | — | EP | claimed |
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | BERRY DAVID ALLEN (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0103464-B1 | DIAMINOPYRIMIDINES AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-11-17 | — | — | EP | disclosed |
| US-4532240-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| EP-0103464-A2 | Diaminopyrimidines and their production | WARNER-LAMBERT COMPANY (US) | 1984-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | ABCB1, ABCC1, DPYD | DHFR 81/4885MTR 3252/4885KDM4E 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.